Novo Says Still Some Uncertainty on Tresiba Costs

Oct. 31 (Bloomberg) -- Novo Nordisk A/S Chief Financial Officer Jesper Brandgaard talks about the company's third-quarter profit reported today, sales forecast and the launch of its new diabetes treatment, Tresiba. He speaks from Bagsvaerd, Denmark, with Caroline Hyde on Bloomberg Television's "The Pulse." (Source: Bloomberg)

Most Recent Videos

Greece Credit Rating May be Cut by S&P
28:18 - Jan. 28 -- Bloomberg’s Mark Crumpton reports on today’s top world news stories on “Bottom Line.”
  • ECB's Nouy: Greek Banks Strong Enough to Survive Crisis
  • How Investors Are Reacting to the Fed's Policy Statement
  • Marriott’s Bid to Block Wi-Fi Gets Criticism at FCC